Marie V Nelson1, Marry M van den Heuvel-Eibrink2, Norbert Graf3, Jeffrey S Dome1. 1. Division of Oncology, Children's National Hospital and the George Washington University School of Medicine and Health Sciences, Washington DC, USA. 2. Department of Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. 3. Department of Pediatric Oncology, University Hospital of Saarland, Homburg, Germany.
Abstract
PURPOSE OF REVIEW: The treatment of Wilms tumor is one of the great achievements in the field of oncology. One of the key success factors has been improved risk stratification, enabling augmentation or reduction of therapy depending on a patient's risk of relapse. This article highlights the evolution of clinical and biological prognostic markers that have been applied in the treatment of Wilms tumor. RECENT FINDINGS: Historically, tumor stage and histology were the sole determinants of Wilms tumor treatment. Recent clinical trials conducted by the Children's Oncology Group (COG) and the International Society of Pediatric Oncology (SIOP) Renal Tumor Study Group have expanded the menu of prognostic factors to include histologic and volumetric response to therapy and tumor-specific loss of heterozygosity (LOH) at chromosomes 1p and 16q. Augmentation of therapy has been able to overcome the adverse risk factors. An emerging prognostic marker is chromosome 1q gain, will be incorporated into future clinical trials. SUMMARY: The application of new clinical and biological prognostic factors has created unprecedented ability to tailor therapy for Wilms tumor, accompanied with improved outcomes. Current and future trials will continue to enhance precision medicine for Wilms tumor.
PURPOSE OF REVIEW: The treatment of Wilms tumor is one of the great achievements in the field of oncology. One of the key success factors has been improved risk stratification, enabling augmentation or reduction of therapy depending on a patient's risk of relapse. This article highlights the evolution of clinical and biological prognostic markers that have been applied in the treatment of Wilms tumor. RECENT FINDINGS: Historically, tumor stage and histology were the sole determinants of Wilms tumor treatment. Recent clinical trials conducted by the Children's Oncology Group (COG) and the International Society of Pediatric Oncology (SIOP) Renal Tumor Study Group have expanded the menu of prognostic factors to include histologic and volumetric response to therapy and tumor-specific loss of heterozygosity (LOH) at chromosomes 1p and 16q. Augmentation of therapy has been able to overcome the adverse risk factors. An emerging prognostic marker is chromosome 1q gain, will be incorporated into future clinical trials. SUMMARY: The application of new clinical and biological prognostic factors has created unprecedented ability to tailor therapy for Wilms tumor, accompanied with improved outcomes. Current and future trials will continue to enhance precision medicine for Wilms tumor.
Authors: Sophie E van Peer; Janna A Hol; Alida F W van der Steeg; Martine van Grotel; Godelieve A M Tytgat; Annelies M C Mavinkurve-Groothuis; Geert O R Janssens; Annemieke S Littooij; Ronald R de Krijger; Marjolijn C J Jongmans; Marc R Lilien; Jarno Drost; Roland P Kuiper; Harm van Tinteren; Marc H W A Wijnen; Marry M van den Heuvel-Eibrink Journal: J Clin Med Date: 2021-11-26 Impact factor: 4.241
Authors: Justine N van der Beek; Tom A Watson; Rutger A J Nievelstein; Hervé J Brisse; Carlo Morosi; Henrique M Lederman; Ana Coma; Maria M Gavra; Kristina Vult von Steyern; Karoly Lakatos; Luc Breysem; Edit Varga; Hubert Ducou Le Pointe; Maarten H Lequin; Jürgen F Schäfer; Hans-Joachim Mentzel; Andreas M Hötker; Giuseppina Calareso; Sophie Swinson; Martin Kyncl; Claudio Granata; Michael Aertsen; Pier Luigi Di Paolo; Ronald R de Krijger; Norbert Graf; Øystein E Olsen; Jens-Peter Schenk; Marry M van den Heuvel-Eibrink; Annemieke S Littooij Journal: J Magn Reson Imaging Date: 2021-08-06 Impact factor: 5.119